Explore
Validate
Learn
Western blot
Immunohistochemistry
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-51339 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- SMYD2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- The antibody detects endogenous levels of total SMYD2 protein.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 2.2 mg/mL
- Storage
- -20°C
Submitted references Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry.
SMYD2 promoter DNA methylation is associated with abdominal aortic aneurysm (AAA) and SMYD2 expression in vascular smooth muscle cells.
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Engqvist H, Parris TZ, Kovács A, Rönnerman EW, Sundfeldt K, Karlsson P, Helou K
Frontiers in oncology 2020;10:162
Frontiers in oncology 2020;10:162
SMYD2 promoter DNA methylation is associated with abdominal aortic aneurysm (AAA) and SMYD2 expression in vascular smooth muscle cells.
Toghill BJ, Saratzis A, Freeman PJ, Sylvius N, UKAGS collaborators, Bown MJ
Clinical epigenetics 2018;10:29
Clinical epigenetics 2018;10:29
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W, Chen F, Fei X, Yang X, Lu X
Medical science monitor : international medical journal of experimental and clinical research 2018 Oct 15;24:7357-7365
Medical science monitor : international medical journal of experimental and clinical research 2018 Oct 15;24:7357-7365
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Analysis of SMYD2 expression in patients with PTC. ( A, B ) IHC staining of SMYD2 in adjacent thyroid tissues ( A ) and PTC tissues ( B ). ( C ) Correlation between relative protein level of SMYD2 and different TNM stages. ( D ) RNA levels of SMYD2 were examined in PTC tissues and adjacent thyroid tissues. * P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Protein expression of clear-cell (CCC)-associated biomarkers (A) , endometrioid (EC)-associated biomarkers (B) , and mucinous ovarian carcinoma (MC)-associated biomarkers (C) . Representative immunohistochemical staining intensities showing protein expression (negative vs. positive) in ovarian tumor cells for histotype-associated biomarkers (400 x magnification).
